Old dogma, new tricks—21st Century phage therapy

  title={Old dogma, new tricks—21st Century phage therapy},
  author={Karl A Thiel},
  journal={Nature Biotechnology},
  • K. Thiel
  • Published 2004
  • Medicine
  • Nature Biotechnology
As antibiotic resistant bacteria threaten a public health crisis, biotechnology is turning to bacteriophages, nature's tiniest viruses. But can phage therapy overcome its historical baggage? 

Reinventing phage therapy: are the parts greater than the sum?

Although whole phage continue to generate interest as an alternative to antibiotics, focus is shifting to the use of purified phage components as antibacterial agents.

The efficacy of bacterial viruses against multi-resistant Escherichia coli: from isolation to pharmacology

The increase of multi-resistant bacteria highlights that the golden era of antibiotics is ending and that alternative treatmentsare urgently needed. Phages have been historically used to treat bact

Phage therapy’s latest makeover

As issues of product consistency, standardization and specificity are being tackled, can phage therapeutics—long oversold and overhyped—finally realize their antibacterial potential?

The Magistral Phage

Belgium is now implementing a pragmatic phage therapy framework that centers on the magistral preparation (compounding pharmacy in the US) of tailor-made phage medicines.

Characterization of a novel, biofilm dispersing, lytic bacteriophage against drug‐resistant Enterobacter cloacae

A novel bacteriophage, En5822, isolated from the environment against Enterobacter cloacae and exploring its application as an alternate antimicrobial is characterized.

Revitalizing Phage Therapy in Combating Multi-Drug Resistant Bacteria

The idea of engineering “broad-spectrum phage” to overcome a wide range of resistant bacterial infections, and its advantages over antibiotics, individual phage, and phage cocktails are proposed.

Introducing yesterday's phage therapy in today's medicine

The inherent potential of phages as natural biological bacterium controllers can only be put to use if the potential of the coevolutionary aspect of the couplet phage–bacterium is fully acknowledged and understood.

Phage therapy and phage control: to be revisited urgently!!

Renewed attention should be directed to the use of phages as antimicrobials in medicine as well as in the health and the agro-food sector.

Clinical Implications of Pseudomonas aeruginosa: Antibiotic Resistance, Phage & Antimicrobial Peptide Therapy

Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that is found ubiquitously in the environment. It is also the cause of nosocomial infections, which affects patients with cystic ...

Article Review: Phage Therapy is a Potential Alternative for Antimicrobial Agents

This review focuses on the use of bacteriophage for the treatment of bacterial infections, especially multidrug-resistant bacteria.



Linezolid resistance in a clinical isolate of Staphylococcus aureus

Bacteriophage K1-5 Encodes Two Different Tail Fiber Proteins, Allowing It To Infect and Replicate on both K1 and K5 Strains of Escherichia coli

Experimental evidence that mature phage particles contain both tail fiber proteins, and mutational analysis indicates that each protein can be independently inactivated, suggests that this family of phages can broaden host range by horizontal gene transfer.

Concerns raised over declining antiinfectives R&D

  • J. Fox
  • Medicine
    Nature Biotechnology
  • 2003
B biotech and pharmaceutical companies are more likely to take over development of such vaccines at these later stages, whereas they would not have during the early, riskiest stage of development, and officials point to a distinct trend toward fewer antiinfective agents being approved per year over the past 20 years.

Characterization of Vancomycin-Resistant Enterococcus faecium Isolates from the United States and Their Susceptibility In Vitro to Dalfopristin-Quinupristin

Multiple drug resistance was very common among these isolates of vancomycin-resistant E. faecium, while dalfopristin-quinupristin inhibited the majority at concentrations that are likely to be clinically relevant.

for Disease Control, the Food and Drug Administration and the US National Institutes of Health

  • A Public Health Action Plan to Combat Antimicrobial Resistance (CDC, FDA & NIH, June,
  • 2000